5 more leprosy facilities found to have tested drug on patients
The drug 'Koha' stored at Kikuchi-Keifuen, a national sanitarium for leprosy patients in Koshi, Kumamoto Prefecture. Blueish-blackish powder can be seen inside the glass containers. The photo was taken on Dec. 8, 2022. (Asahi Shimbun file photo)
Five more national leprosy sanitariums during and after World War II have reported administering an experimental drug called "Koha" to residents that caused severe side effects in some patients.
The disclosures follow the release of an investigative report by the Kikuchi-Keifuen sanatorium located in Koshi, Kumamoto Prefecture, in June 2024, disclosing the practice, which has since prompted investigations at other facilities.
The Asahi Shimbun contacted 12 national sanatoriums, excluding Kikuchi-Keifuen, by June this year.
Based on preserved documents and medical records, the administration of Koha was confirmed at the National Suruga sanatorium in Shizuoka Prefecture; Oshima-Seishoen in Takamatsu; Tama-Zenshoen in Tokyo; Nagashima-Aiseien in Okayama Prefecture; and Hoshizuka-Keiaien in Kagoshima Prefecture.
Koha, composed of cryptocyanin, a photosensitive dye, was developed under the former Imperial Japanese Army. The military was interested in its application for frostbite and burn treatment in cold-weather operations.
The military commissioned the research of Koha to Kumamoto medical university, which is now the School of Medicine at Kumamoto University. After some apparent success in tuberculosis patients, which involved bacteria similar to mycobacterium leprae, the drug was tested on leprosy patients.
The director of Kikuchi-Keifuen was commissioned by the 7th Research Center of the Army Technical Headquarters to conduct a trial administration of Koha.
It was conducted on at least 472 residents of the sanatorium between 1942 and 1947. Nine patients died during the trial period, with two deaths suspected to be directly linked to Koha.
At the Suruga sanatorium, a thorough review of all 998 residents' medical records is under way to determine the drug's use.
Shinichi Kitajima, the sanatorium director, confirmed that the use of Koha was found in post-war medical records. Staff members bound by confidentiality are carefully reviewing the records one by one. He said the task 'will take time to fully uncover the facts.'
'There is a possibility that more unknown facts will come to light. We need to establish rules for preserving medical records and documents,' Kitajima added.
Information regarding the administration of Koha at Tama-Zenshoen and Oshima-Seishoen was found in the 1947 issue of the journal of dermatology and venereology, which is now preserved at the National Hansen's Disease Museum.
According to the journal, the director of Tama-Zenshoen reported that of 175 cases, the use was discontinued in 72 within three months, while 103 continued for four to eight months. The facility needed to stop administrating Koha in 57 cases due to the general deterioration of the resident's health.
The director of Oshima-Seishoen also reported administering Koha to 180 people.
'There were many side effects of the drug. But they diminished after stopping the drug,' he wrote.
The administration of the drug at Oshima-Seishoen ran from 1944 to 1946, which overlapped with the period of operation at Kikuchi-Keifuen.
Records regarding Koha's administration were also found in Nagashima-Aiseien's institutional journal and the residents' association magazine at Hoshizuka-Keiaien.
Other facilities said that the number of records is too large and that they are considering how to proceed with their research.
'Investigations should be conducted at sanatoriums across the country,' said Akira Ota, acting chairperson of the Kikuchi-Keifuen residents' association.
According to the health ministry, as of May this year, there are 639 residents in national sanatoriums, with an average age of 88.8 years old.
SUFFERING FROM SIDE EFFECTS
A doctor at Oshima-Seishoen told Tsuneji Matsumoto, who is now 93, along with other young residents around early 1944, that 'A new drug for leprosy has been developed. You'll take it.'
Records confirm that Koha was administered at this facility.
According to Matsumoto, who entered the facility in July 1942 and still lives there, the drug was given under the pretext of leprosy treatment.
The 'thin, flat tablet' was taken once a day before noon. Afterward, he felt dazed and his vision deteriorated. He remembers crawling along the hallways saying, 'I can't see, I can't see.' Then, he became hospitalized.
He recalls others around him suffering from fevers or festering wounds. One woman lost her hair and cried. Due to these painful side effects, some patients said they didn't want to take the medicine anymore.
However, the doctor said that, 'It's working because you're having a reaction,' and continued administering it.
Some residents pretended to have taken the pill, hiding it under their tongues and spitting it out later.
However, this ruse was eventually discovered. Nurses began checking to ensure that each tablet was swallowed.
Matsumoto recalls the pill treatments lasting from six months to a year. One day, without explanation, the prescription was abruptly halted. He later heard that the military ordered the administrating of Koha.
'I believe that the doctors at the sanatorium weren't able to refuse,' he said. 'The military was terrifying.'
(This article was compiled from reports written by Satoko Onuki, Ryutaro Ito and Kei Yoshida.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Asahi Shimbun
3 days ago
- Asahi Shimbun
5 more leprosy facilities found to have tested drug on patients
The drug 'Koha' stored at Kikuchi-Keifuen, a national sanitarium for leprosy patients in Koshi, Kumamoto Prefecture. Blueish-blackish powder can be seen inside the glass containers. The photo was taken on Dec. 8, 2022. (Asahi Shimbun file photo) Five more national leprosy sanitariums during and after World War II have reported administering an experimental drug called "Koha" to residents that caused severe side effects in some patients. The disclosures follow the release of an investigative report by the Kikuchi-Keifuen sanatorium located in Koshi, Kumamoto Prefecture, in June 2024, disclosing the practice, which has since prompted investigations at other facilities. The Asahi Shimbun contacted 12 national sanatoriums, excluding Kikuchi-Keifuen, by June this year. Based on preserved documents and medical records, the administration of Koha was confirmed at the National Suruga sanatorium in Shizuoka Prefecture; Oshima-Seishoen in Takamatsu; Tama-Zenshoen in Tokyo; Nagashima-Aiseien in Okayama Prefecture; and Hoshizuka-Keiaien in Kagoshima Prefecture. Koha, composed of cryptocyanin, a photosensitive dye, was developed under the former Imperial Japanese Army. The military was interested in its application for frostbite and burn treatment in cold-weather operations. The military commissioned the research of Koha to Kumamoto medical university, which is now the School of Medicine at Kumamoto University. After some apparent success in tuberculosis patients, which involved bacteria similar to mycobacterium leprae, the drug was tested on leprosy patients. The director of Kikuchi-Keifuen was commissioned by the 7th Research Center of the Army Technical Headquarters to conduct a trial administration of Koha. It was conducted on at least 472 residents of the sanatorium between 1942 and 1947. Nine patients died during the trial period, with two deaths suspected to be directly linked to Koha. At the Suruga sanatorium, a thorough review of all 998 residents' medical records is under way to determine the drug's use. Shinichi Kitajima, the sanatorium director, confirmed that the use of Koha was found in post-war medical records. Staff members bound by confidentiality are carefully reviewing the records one by one. He said the task 'will take time to fully uncover the facts.' 'There is a possibility that more unknown facts will come to light. We need to establish rules for preserving medical records and documents,' Kitajima added. Information regarding the administration of Koha at Tama-Zenshoen and Oshima-Seishoen was found in the 1947 issue of the journal of dermatology and venereology, which is now preserved at the National Hansen's Disease Museum. According to the journal, the director of Tama-Zenshoen reported that of 175 cases, the use was discontinued in 72 within three months, while 103 continued for four to eight months. The facility needed to stop administrating Koha in 57 cases due to the general deterioration of the resident's health. The director of Oshima-Seishoen also reported administering Koha to 180 people. 'There were many side effects of the drug. But they diminished after stopping the drug,' he wrote. The administration of the drug at Oshima-Seishoen ran from 1944 to 1946, which overlapped with the period of operation at Kikuchi-Keifuen. Records regarding Koha's administration were also found in Nagashima-Aiseien's institutional journal and the residents' association magazine at Hoshizuka-Keiaien. Other facilities said that the number of records is too large and that they are considering how to proceed with their research. 'Investigations should be conducted at sanatoriums across the country,' said Akira Ota, acting chairperson of the Kikuchi-Keifuen residents' association. According to the health ministry, as of May this year, there are 639 residents in national sanatoriums, with an average age of 88.8 years old. SUFFERING FROM SIDE EFFECTS A doctor at Oshima-Seishoen told Tsuneji Matsumoto, who is now 93, along with other young residents around early 1944, that 'A new drug for leprosy has been developed. You'll take it.' Records confirm that Koha was administered at this facility. According to Matsumoto, who entered the facility in July 1942 and still lives there, the drug was given under the pretext of leprosy treatment. The 'thin, flat tablet' was taken once a day before noon. Afterward, he felt dazed and his vision deteriorated. He remembers crawling along the hallways saying, 'I can't see, I can't see.' Then, he became hospitalized. He recalls others around him suffering from fevers or festering wounds. One woman lost her hair and cried. Due to these painful side effects, some patients said they didn't want to take the medicine anymore. However, the doctor said that, 'It's working because you're having a reaction,' and continued administering it. Some residents pretended to have taken the pill, hiding it under their tongues and spitting it out later. However, this ruse was eventually discovered. Nurses began checking to ensure that each tablet was swallowed. Matsumoto recalls the pill treatments lasting from six months to a year. One day, without explanation, the prescription was abruptly halted. He later heard that the military ordered the administrating of Koha. 'I believe that the doctors at the sanatorium weren't able to refuse,' he said. 'The military was terrifying.' (This article was compiled from reports written by Satoko Onuki, Ryutaro Ito and Kei Yoshida.)
Asahi Shimbun
6 days ago
- Asahi Shimbun
1st tick-borne virus infection of pet cat reported in Kanto
Stray cats that are unrelated to the domestic cat in Ibaraki Prefecture that tested postive for the severe fever with thrombocytopenia syndrome (SFTS) virus in May (Asahi Shimbun file photo) A domestic cat in Ibaraki Prefecture has been confirmed to have contracted a potentially deadly tick-transmitted disease, believed to be the first reported case in the Kanto region. The cat, which later died, tested positive for the severe fever with thrombocytopenia syndrome (SFTS) virus in May. The same month, a veterinarian treating a hospitalized cat in Mie Prefecture died from SFTS, prompting a warning to be issued across the nation. Experts are warning as areas at risk of the infectious disease are spreading. Ken Maeda, head of the veterinary science department of the Japan Institute for Health Security, said that he could not comment on individual infection cases but added, 'The risk is rising even in the Kanto region, too. We need to be prepared with a sense of urgency.' Symptoms of SFTS include fever, vomiting and diarrhea. The fatality rate in humans is 30 percent and in cats it is as high as 60 percent. Infections have been reported mainly in western Japan. The first infection confirmed in the Kanto region was a 1-year-old female cat, according to Ibaraki prefectural and other officials. The cat had been kept indoors, but in late April, after temporarily escaping outdoors, many small ticks were found embedded in her ears. The cat was taken to a nearby veterinary hospital. On May 9, after the ticks were removed, the cat was seen again with a high fever of 40.9 degrees, loss of appetite and vomiting. The following day, the cat also developed jaundice. The veterinarian, suspecting SFTS from the symptoms, contacted the prefectural government on May 12. Prefectural workers then tested the cat's blood components, which were confirmed to be infected with the SFTS virus. The cat was nursed at the owner's home in an isolation cage, but died on May 12. According to the prefectural government, a notice was issued in late May to veterinarians through the prefectural veterinary medical association, calling for infection control measures to be taken. In the prefecture, six cats and two dogs have been tested so far for the suspected virus, including this case. This was the first positive test for the virus, according to the prefecture. No transmission from the cat to the owner, veterinarian or other humans has been confirmed in the prefecture, officials said. According to the Japan Institute for Health Security, the number of SFTS infection cases has been on the rise since the virus was first confirmed in Japan in 2013. More than 100 cases were reported annually from 2021 to 2024, and a record 134 infections were logged in 2023. In addition to humans, cats and dogs have been mostly infected in western Japan. However, the infections spread to the Chubu region, with cases in Aichi and Shizuoka prefectures in 2021 and Toyama Prefecture in 2022. In the Kanto region and northern Japan, there had been no officially confirmed cases in humans, cats or dogs except for a case in which a man in his 70s in Chiba Prefecture was infected in 2017 and this was discovered four years later. The Tokyo Veterinary Medical Association prepared a manual for veterinarians in 2021 and a video on preventing SFTS infections in 2022. Kiyoshi Nakagawa, vice chair of the association, said, 'We have been thinking that a case could be confirmed at any time in Tokyo or the Kanto region.' Maeda of the Japan Institute for Health Security said to prevent infections, 'If it is a cat, keep it indoors, never directly touch its bodily fluids when it is sick and disinfect the cage. If you take measures such as wearing gloves and masks, you can reduce the risk considerably.'
Yomiuri Shimbun
21-06-2025
- Yomiuri Shimbun
Rapid Spread of Whooping Cough: Alert Should Be Raised to Prevent Infection among Infants
The number of patients with whooping cough, which is characterized by severe coughing that can last for a prolonged period of time, has surged. Caution must be strengthened, particularly for babies, as they are more prone to developing severe symptoms if they become infected. Whooping cough is transmitted through cough droplets or contact with hands that are contaminated with a certain type of bacteria. It is significantly more contagious than seasonal influenza and other diseases. This year, the number of patients has exceeded 28,000 nationwide. The figure has already significantly surpassed the 2019 figure of 16,845, which was the record high in recent years. Moreover, the weekly number of patients in early June topped 3,000, indicating the rapid spread of infection. The infection is spreading across all age groups, but it is particularly prevalent among children aged 10 or younger. Caution is especially needed for infants. If babies are infected within the first six months after they are born, they are at high risk of losing their lives from developing respiratory distress and pneumonia. At least two infants died this year due to whooping cough. Those related to such entities as childcare facilities and schools must be vigilant for infection clusters. It is important for people who have symptoms, including adults, to quickly see a doctor to prevent the spread of infection. Whooping cough caused many deaths until the 1940s, but shortly after World War II, vaccinations began to be administered, allowing those who became infected to only have mild symptoms. However, as the symptoms are mild, people could spread the disease without knowing it. It is hoped that people who are coughing wear a mask and follow certain etiquette to prevent the spread of infection. It is also crucial to check whether basic measures against infection are taken, such as hand washing. Infants are eligible to receive vaccinations against whooping cough at public expense. Currently, they are supposed to receive a total of four doses at various intervals after they are 2 months old. Parents and guardians are urged to have infants vaccinated as soon as they reach 2 months of age. It is also effective for family members to voluntarily receive additional vaccinations in order to protect infants. However, there has been a surge in demand for such additional vaccinations, raising concerns in the medical field about a shortage of the vaccines for voluntary shots. It is hoped that medical institutions will prioritize people who are more in need of the vaccines, such as family members who have close contact with babies. Treatment usually involves the use of antimicrobial drugs but recently there has been an increase in drug-resistant bacteria that do not respond to antimicrobial drugs. The current outbreak is believed to be linked to the spread of such bacteria. The drug-resistant bacteria have been spreading in countries and regions such as China. There also have been a series of reports of the bacteria in Japan since late last year. Patients infected with such drug-resistant bacteria require different antimicrobial drugs for treatment. It is hoped that medical associations and other relevant groups will make efforts to make appropriate treatment methods widely known. (From The Yomiuri Shimbun, June 21, 2025)
